Neuromuscular disease: Difference between revisions

Jump to navigation Jump to search
(/* ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT) {{cite journal| author=Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al.| title=AC...)
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
{{Infobox_Disease |
{{Infobox_Disease |
   Name          = {{PAGENAME}} |
   Name          = {{PAGENAME}} |
Line 17: Line 18:
Neuromuscular diseases are those that affect the muscles and/or their nervous control. In general, problems with nervous control can cause [[spasticity]] or [[paralysis]], depending on the location and nature of the problem. A large proportion of [[neurological disorder]]s leads to problems with movement, ranging from [[cerebrovascular accident]] (stroke) and [[Parkinson's disease]] to [[Creutzfeldt-Jakob disease]].
Neuromuscular diseases are those that affect the muscles and/or their nervous control. In general, problems with nervous control can cause [[spasticity]] or [[paralysis]], depending on the location and nature of the problem. A large proportion of [[neurological disorder]]s leads to problems with movement, ranging from [[cerebrovascular accident]] (stroke) and [[Parkinson's disease]] to [[Creutzfeldt-Jakob disease]].


==Symptoms==
Symptoms of muscle disease may include
* [[Weakness]] or
* [[Spasticity]]/[[rigidity]]
* [[Myoclonus]]
* [[myalgia]] ([[muscle pain]]).
==Laboratory Findings==
Diagnostic procedures that may reveal muscular disorders include testing [[creatine kinase]] levels in the blood and [[electromyography]] (measuring electrical activity in muscles).
==Causes==
==Causes==
* Diseases of the [[motor end plate]] include
* Diseases of the [[motor end plate]] include
Line 33: Line 24:
** [[Tetanus]]
** [[Tetanus]]
** [[Botulism]]
** [[Botulism]]
* The [[myopathy|myopathies]] are all diseases affecting the muscle itself, rather than its nervous control.
* The [[myopathy|myopathies]] are all diseases affecting the muscle itself, rather than its nervous control.
** [[Muscular dystrophy]] leads to progressive loss of strength, high dependence and decreased life span.
** [[Muscular dystrophy]] leads to progressive loss of strength, high dependence and decreased life span.
Line 41: Line 31:
*** [[Dermatomyositis]]
*** [[Dermatomyositis]]
*** [[Inclusion body myositis]]  
*** [[Inclusion body myositis]]  
** Other causes
** Other causes
*** [[Tumor]]s of muscle
*** [[Tumor]]s of muscle
**** Smooth muscle: [[leiomyoma]] (benign, very common in the [[uterus]]), [[leiomyosarcoma]] (malignant, very rare)
**** Smooth muscle: [[leiomyoma]] (benign, very common in the [[uterus]]), [[leiomyosarcoma]] (malignant, very rare)
**** Striated muscle: [[rhabdomyoma]] (benign) and [[rhabdomyosarcoma]] (malignant) - both very rare
**** Striated muscle: [[rhabdomyoma]] (benign) and [[rhabdomyosarcoma]] (malignant) - both very rare
**** [[Metastasis]] from elsewhere (e.g. [[lung cancer]])
**** [[Metastasis]] from elsewhere (e.g. [[lung cancer]])
*** Injury [[Injury|Injuries]] -  of muscles include [[wound]]s and [[strain]]s.
==Symptoms==


*** Injury[[Injury|Injuries]] - of muscles include [[wound]]s and [[strain]]s.
Symptoms of muscle disease may include
* [[Weakness]] or
* [[Spasticity]]/[[rigidity]]
* [[Myoclonus]]
* [[myalgia]] ([[muscle pain]]).
 
==Laboratory Findings==
Diagnostic procedures that may reveal muscular disorders include testing [[creatine kinase]] levels in the blood and [[electromyography]] (measuring electrical activity in muscles).
 
== ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT) <ref name="pmid16935995">{{cite journal| author=Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al.| title=ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. | journal=Circulation | year= 2006 | volume= 114 | issue= 10 | pages= e385-484 | pmid=16935995 | doi=10.1161/CIRCULATIONAHA.106.178233 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16935995}}</ref> ==
 
=== Recommendations for Neuromuscular Disorders ===
 
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class I]]
 
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Patients with neuromuscular disorders who have ventricular arrhythmias should generally be treated in the same manner as patients without neuromuscular disorders. ([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]]). <nowiki>"</nowiki>
|}
 
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIa]]
 
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Permanent pacemaker insertion may be considered for neuromuscular diseases such as myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb dystrophy, and peroneal muscular atrophy with any degree of AV block (including first-degree AV block) with or without symptoms, because there may be unpredictable progression of AV conduction disease. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|}


==See also==
==Related Chapters==
*[[Muscle]]
*[[Muscle]]
*[[ICD-10_Chapter_XIII:_Diseases_of_the_musculoskeletal_system_and_connective_tissue]]
*[[ICD-10_Chapter_XIII:_Diseases_of_the_musculoskeletal_system_and_connective_tissue]]
*[[Centronuclear myopathy (including myotubular myopathy)|Centronuclear myopathy]]
*[[Centronuclear myopathy (including myotubular myopathy)|Myotubular myopathy]]
==References==
{{reflist|2}}


[[Category:Muscular system]]
[[Category:Muscular system]]
*[[Centronuclear myopathy (including myotubular myopathy)|Centronuclear myopathy]]
*[[Centronuclear myopathy (including myotubular myopathy)|Myotubular myopathy]]


[[nl:Spierziekte]]
[[nl:Spierziekte]]
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 13:17, 5 October 2012

Neuromuscular disease
MeSH D009468

Overview

Neuromuscular disease is a very broad term that encompasses many diseases and ailments that either directly (via intrinsic muscle pathology) or indirectly (animal muscle in general.

Neuromuscular diseases are those that affect the muscles and/or their nervous control. In general, problems with nervous control can cause spasticity or paralysis, depending on the location and nature of the problem. A large proportion of neurological disorders leads to problems with movement, ranging from cerebrovascular accident (stroke) and Parkinson's disease to Creutzfeldt-Jakob disease.

Causes

Symptoms

Symptoms of muscle disease may include

Laboratory Findings

Diagnostic procedures that may reveal muscular disorders include testing creatine kinase levels in the blood and electromyography (measuring electrical activity in muscles).

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT) [1]

Recommendations for Neuromuscular Disorders

Class I
"1. Patients with neuromuscular disorders who have ventricular arrhythmias should generally be treated in the same manner as patients without neuromuscular disorders. (Level of Evidence: A). "
Class IIa
"1. Permanent pacemaker insertion may be considered for neuromuscular diseases such as myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb dystrophy, and peroneal muscular atrophy with any degree of AV block (including first-degree AV block) with or without symptoms, because there may be unpredictable progression of AV conduction disease. (Level of Evidence: B)"

Related Chapters

References

  1. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M; et al. (2006). "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (10): e385–484. doi:10.1161/CIRCULATIONAHA.106.178233. PMID 16935995.

nl:Spierziekte Template:WikiDoc Sources